Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Instil Bio (TIL)
NASDAQ:TIL
Holding TIL?
Track your performance easily
TIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $92.00
Previous Close$33.63
Volume167.10K
Average Volume (3M)285.81K
Market Cap
$218.73M
Enterprise Value$154.09M
Total Cash (Recent Filing)$148.58M
Total Debt (Recent Filing)$83.95M
Price to Earnings (P/E)―
Beta6.23
Next Earnings
Mar 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-18.39
Shares Outstanding6,503,913
10 Day Avg. Volume142,275
30 Day Avg. Volume285,814
Standard Deviation0.63
R-Squared0.02
Alpha0.00425
Financial Highlights & Ratios
Price to Book (P/B)1.11
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.41
Forecast
1Y Price Target
$150.00Price Target Upside349.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Instil Bio News
PremiumCompany Announcements
Instil Bio Outlines Oncology Strategy and Collaborative EffortsBulls Say, Bears Say
Bulls Say
Clinical Development PlansInstil Bio released its highly anticipated clinical development plans for the company's PD-L1 x VEGF bispecific antibody, SYN-2510.
Investor InterestIncreased investor interest in the PD-1xVEGF space is seen as supportive of building enthusiasm for the mechanism, with Instil shares expected to rise as enthusiasm grows.
Strategic CollaborationsInstil entered into a collaboration agreement with ImmuneOnco for the ex-China rights to SYN-2510, a novel PD-L1xVEGF bispecific antibody.
Bears Say
Market OutlookReducing price target to $32/share after updating the model and taking into account the current market dynamics surrounding Instil shares.
Product StrategyThere have been over 10 trial terminations for combining PD-1/L1 mAbs with anti-VEGF mAbs, showcasing how ineffective this strategy has been, historically.
Risk ProfileThe stock is characterized as speculative risk, indicating a higher level of uncertainty and potential volatility.
---
TIL FAQ
What was Instil Bio’s price range in the past 12 months?
Instil Bio lowest stock price was $6.07 and its highest was $92.00 in the past 12 months.
What is Instil Bio’s market cap?
Currently, no data Available
When is Instil Bio’s upcoming earnings report date?
Instil Bio’s upcoming earnings report date is Mar 10, 2025 which is in 109 days.
How were Instil Bio’s earnings last quarter?
Instil Bio released its earnings results on Aug 13, 2024. The company reported -$2.29 earnings per share for the quarter, beating the consensus estimate of -$2.98 by $0.69.
Is Instil Bio overvalued?
According to Wall Street analysts Instil Bio’s price is currently Undervalued.
Does Instil Bio pay dividends?
Instil Bio does not currently pay dividends.
What is Instil Bio’s EPS estimate?
Instil Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Instil Bio have?
Instil Bio has 6,503,913 shares outstanding.
What happened to Instil Bio’s price movement after its last earnings report?
Instil Bio reported an EPS of -$2.29 in its last earnings report, beating expectations of -$2.98. Following the earnings report the stock price went up 1.063%.
Which hedge fund is a major shareholder of Instil Bio?
Among the largest hedge funds holding Instil Bio’s share is Baker Bros Advisors LP. It holds Instil Bio’s shares valued at N/A.
---
Instil Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$150.00 (349.37% Upside)
$150.00 (349.37% Upside)
Hedge Fund Trend
Decreased
By 325.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 16.6%
Last 30 Days ▼ 15.7%
Last 30 Days ▼ 15.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
380.42%
12-Months-Change
Fundamentals
Return on Equity
-48.65%
Trailing 12-Months
Asset Growth
-27.92%
Trailing 12-Months
Company Description
Instil Bio
Instil Bio Inc is a clinical-stage cell therapy company. It is developing tumor infiltrating lymphocytes for the treatment of cancer.
---
TIL Stock 12 Month Forecast
Average Price Target
$150.00
▲(349.37% Upside)
Technical Analysis
Best Analysts Covering TIL
1 Year
1 Year Success Rate
6/17 ratings generated profit
1 Year Average Return
+8.60%
reiterated a buy rating 24 days ago
Copying Jack Allen's trades and holding each position for 1 Year would result in 35.29% of your transactions generating a profit, with an average return of +8.60% per trade.
---